Drug sensitivity profiling identifies potential therapies for myeloid neoplasm with eosinophilia driven by a novel G3BP1-PDGFRB fusion gene-Reference-Cited by-同舟云学术

Drug sensitivity profiling identifies potential therapies for myeloid neoplasm with eosinophilia driven by a novel G3BP1-PDGFRB fusion gene

Published:2023-12-29 Issue: Volume: Page:1-5
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Wang Jianli¹,Xu Lei²^ORCID,Li Yuqing²³,Wang Jun²,Shao Yangliu²³,Lai Weifeng⁴,Yong Jun⁴,Zhao Ling⁵,Wei Xuemin⁵,Gao Chunji⁵,Liu Daihong⁵,Gao Xiaoning²,Zhang Yongqing¹⁵

Affiliation:

1. Department of Internal Medicine, Hebei North University, Zhangjiakou, China

2. Department of Hematology, Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China

3. Graduate School of Chinese PLA General Hospital, Beijing, China

4. Suzhou Geekgene Technology Co. Ltd., Beijing, China

5. Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China

Funder

Beijing Nova Program

National Key Research and Development Program of China

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2299298

Reference8 articles.

1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

2. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

3. Myeloid neoplasms with eosinophilia

4. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management

5. A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia